Increased percentage of B cells in patients with more advanced hepatocellular carcinoma

Human Immunology

Volumn 71, Issue 1, 2010, Pages 58-62

  Lin, Jiunn Chang ^a,b,c   Shih, Yung Luen ^b,d   Chien, Pei Ju ^b   Liu, Chien Liang ^a   Lee, Jie Jen ^a   Liu, Tsan Pai ^a   Ko, Wen Ching ^a   Shih, Chwen Ming ^b,e  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d Laboratory Medicine   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

B lymphocyte; Hepatocellular carcinoma; Immunity; Lymphocyte subset; Phagocytosis

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; B LYMPHOCYTE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY CANCER; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GRANULOCYTE; HELPER CELL; HUMAN; LIVER CELL CARCINOMA; LYMPHOCYTE COUNT; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; TUMOR IMMUNITY;

ADULT; AGED; B-LYMPHOCYTES; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHAGOCYTOSIS;

EID: 71249163387     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.10.003     Document Type: Article

References (44)

1. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
2. Cormier J.N., Thomas K.T., Chari R.S., and Pinson C.W. Management of hepatocellular carcinoma. J Gastrointest Surg 10 (2006) 761-780
3. Euvrard S., Kanitakis J., and Claudy A. Skin cancers after organ transplantation. N Engl J Med 348 (2003) 1681-1691
4. Hakim F.T., Flomerfelt F.A., Boyiadzis M., and Gress R.E. Aging, immunity and cancer. Curr Opin Immunol 16 (2004) 151-156
5. Kuss I., Hathaway B., Ferris R.L., Gooding W., and Whiteside T.L. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10 (2004) 3755-3762
6. van Sandick J.W., Boermeester M.A., Gisbertz S.S., ten Berge I.J., Out T.A., van der Pouw Kraan T.C., et al. Lymphocyte subsets and T(h)1/T(h)2 immune responses in patients with adenocarcinoma of the oesophagus or oesophagogastric junction: relation to pTNM stage and clinical outcome. Cancer Immunol Immunother 52 (2003) 617-624
7. Fogar P., Sperti C., Basso D., Sanzari M.C., Greco E., Davoli C., et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 32 (2006) 22-28
8. Campbell M.J., Scott J., Maecker H.T., Park J.W., and Esserman L.J. Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res Treat 91 (2005) 163-171
9. McArdle P.A., Canna K., McMillan D.C., McNicol A.M., Campbell R., and Underwood M.A. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 91 (2004) 541-543
10. Chang L., Gusewitch G.A., Chritton D.B.W., Folz J.C., Lebeck L.K., and Nehlsen-Cannarella S.L. Rapid flow cytometric assay for the assessment of natural killer cell activity. J Immunol Methods 166 (1993) 45-54
11. Piriou L., Chilmonczyk S., Genetet N., and Albina E. Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity in human and in different animal species. Cytometry 41 (2000) 289-297
12. Ashmore L.M., Shopp G.M., and Edwards B.S. Lymphocyte subset analysis by flow cytometry. Comparison of three different staining techniques and effects of blood storage. J Immunol Methods 118 (1989) 209-215
13. Lehmann A.K., Sornes S., and Halstensen A. Phagocytosis: measurement by flow cytometry. J Immunol Methods 243 (2000) 229-242
14. Hause D., Koenigshausen E., Kenel L., Wendel M., Stehr S.N., and Koch T. Leukocyte antibacterial functions are not impaired by perfluorocarbon exposure in vitro. Am J Physiol Lung Cell Mol Physiologist 295 (2008) L134-L142
15. McCloskey T.W., Oyaizu N., Coronesi M., and Pahwa S. Use of a flow cytometric assay to quantitate apoptosis in human lymphocytes. Clin Immunol Immunopathol 71 (1994) 14-18
16. Sigal L.H. Molecular biology and immunology for clinicians 24: phylogeny of the immune system. J Clin Rheumatol 9 (2003) 200-206
17. Lee W.C., Chiang Y.J., Wang H.C., Wang M.R., Lia S.R., and Chen M.F. Functional impairment of dendritic cells caused by murine hepatocellular carcinoma. J Clin Immunol 24 (2004) 145-154
18. Ninomiya T., Akbar S.M., Masumoto T., Horiike N., and Onji M. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 31 (1999) 323-331
19. Kakumu S., Ito S., Ishikawa T., Mita Y., Tagaya T., Fukuzawa Y., et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol 15 (2000) 431-436
20. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 18 (2008) 11-18
21. -restricted NKT cells. Immunol Cell Biol 82 (2004) 323-331
22. Wallace M.E., and Smyth M.J. The role of natural killer cells in tumor control-effectors and regulators of adaptive immunity. Springer Semin Immunopathol 27 (2005) 49-64
23. Cai L., Zhang Z., Zhou L., Wang H., Fu J., Zhang S., et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 129 (2008) 428-437
24. Jinushi M., Takehara T., Tatsumi T., Hiramatsu N., Sakamori R., Yamaquchi S., et al. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 43 (2005) 1013-1020
25. Dunn G.P., Old L.J., and Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 22 (2004) 329-360
26. Rabinovich G.A., Gabrilovich D., and Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25 (2007) 267-296
27. Zitvogel L., Tesniere A., and Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6 (2006) 715-727
28. Zornoza G., Hernandez J.L., Sanz M.L., Fernandez J., Goena I., and Lera J.M. B cells and serum immunoglobulins in patients with breast pathology. Rev Esp Oncol 28 (1981) 17-27
29. Pillai M.R., Balaram P., Abraham T., and Nair M.K. Lymphocyte populations in premalignant lesions and cancer of the oral cavity. Neoplasma 34 (1987) 469-479
30. Saranath D., Mukhopadhyaya R., Rao R.S., Fakih A.R., Naik S.L., and Gangal S.G. Cell-mediated immune status in patients with squamous cell carcinoma of the oral cavity. Cancer 56 (1985) 1062-1070
31. Blattman J.N., and Greenberg P.D. Cancer immunotherapy: a treatment for the masses. Science 305 (2004) 200-205
32. De Visser K.E., Korets L.V., and De Coussens L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7 (2005) 411-423
33. Shah S., Divekar A.A., Hilchey S.P., Cho H.M., Newman C.L., Shin S.U., et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 117 (2005) 574-586
34. Staquicini F.I., Tandle A., Libutti S.K., Sun J., Zigler M., Bar-Eli M., et al. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res 68 (2008) 8419-8428
35. Chapoval A.I., Fuller J.A., Kremlev S.G., Kamdar S.J., and Evans R. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol 161 (1998) 6977-6984
36. Barbera-Guillem E., Nelson M.B., Barr B., Nyhus J.K., May K.F., Feng L., et al. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother 48 (2000) 541-549
37. Perricone M.A., Smith K.A., Claussen K.A., Plog M.S., Hempel D.M., Roberts B.L., et al. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother 27 (2004) 273-281
38. Inoue S., Leitner W.W., Golding B., and Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res 66 (2006) 7741-7747
39. + T cells: role of TGF-beta1. J Immunol 170 (2003) 5897-5911
40. h1 development. J Immunol 163 (1999) 4284-4291
41. Moulin V., Andris F., Thielemans K., Maliszewski C., Urbain J., and Moser M. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med 192 (2000) 475-482
42. Wijesuriya R., Maruo S., Zou J.P., Ogawa M., Umehara K., Yamashita M., et al. B cell-mediated downregulation of IFN-gamma and IL-12 production induced during anti-tumor immune responses in the tumor-bearing state. Int Immunol 10 (1998) 1057-1065
43. Watt V., Ronchese F., and Ritchie D. Resting B cells suppress tumor immunity via an MHC class-II dependent mechanism. J Immunother 30 (2007) 323-332
44. Qin Z., Richter G., Schuler T., Ibe S., Cao X., and Blankenstein T. B cells inhibit induction of T-cell dependent tumor immunity. Nat Med 4 (1998) 627-630